Asset Details
Do you wish to reserve the book?
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
Do you wish to request the book?
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
2016
Overview
The value of bevacizumab (BEV) in recurrent glioblastoma is unclear. Imaging parameters and progression-free survival (PFS) are problematic endpoints. Few data exist on clinical factors influencing overall survival (OS) in unselected patients with recurrent glioblastoma exposed to BEV. We retrospectively analyzed 174 patients with recurrent glioblastoma treated with BEV at two German brain tumor centers. We evaluated general patient characteristics, MGMT status, pretreatment, concomitant oncologic treatment and overall survival. Karnofsky performance score, number of prior chemotherapies, number of prior recurrences and combined treatment with irinotecan (IRI) were significantly associated with OS in univariate analysis. We did not find differences in OS related to sex, age, histology, MGMT status, prior surgical treatment or number of prior radiotherapies. Combined treatment with IRI and higher KPS both remained significantly associated with prolonged survival in multivariate analysis, but patients receiving IRI co-treatment had less advanced disease. Grouping into clinically relevant categories revealed an OS of 16.9 months from start of BEV in patients with first recurrence and KPS ≥ 80 % (n = 25). In contrast, in patients with second recurrence and KPS < 80 %, OS was 3.6 months (n = 27). Our observational data support an early use of BEV in patients with good performance status. The benefit of co-treatment with IRI in our cohort seems to be the result of biased patient recruitment.
Publisher
Springer US,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Antineoplastic Agents, Immunological - therapeutic use
/ Antineoplastic Agents, Phytogenic - therapeutic use
/ Bevacizumab - therapeutic use
/ Brain Neoplasms - drug therapy
/ Brain Neoplasms - epidemiology
/ Camptothecin - analogs & derivatives
/ Camptothecin - therapeutic use
/ Female
/ Humans
/ Karnofsky Performance Status
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - diagnosis
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - epidemiology
/ Oncology
